4th November 2022
From Clinical Trial to Real-World Evidence: Everyday Practice with METex14 Inhibitors in NSCLC
This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).
26th October 2022
Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment
The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.
25th October 2022
Striving for more: personalizing care in patients with psoriatic disease
Striving for more: personalizing care in palients with psoriatic disease. Educational objectives: Understand what patients need and expect from their treatment journey from its outset. Drive the importance of collecting patient reported outcomes on registries and analysing data by gender/age. Consider shared decision-making as essential throughout a patient’s joumey, understanding how it can further treatment personalisation and patient outcomes